Introduction Leptomeningeal disease, in which cancer cells invade the membranes surrounding the brain and spinal cord, remains one of oncology’s most daunting challenges. Patients face rapid neurological decline, and survival is often measured in weeks to months. In a phase 1B study from Moffitt Cancer Center, researchers explored whether combining the immunotherapy drug avelumab with…